Brief: Aptose's New “G3” Formulation Of Luxeptinib Boosts Bioavailability
12/09/2022 13:11
Sept 12 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE’S NEW “G3” FORMULATION OF LUXEPTINIB BOOSTS
BIOAVAILABILITY
Source text for Eikon: ID:nGNX63MJs
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting